Randomized controlled trials myocardial infarction

COMMIT collaborative group. Addition of Clopidogrel to aspirin in 45852 patients with acute myocardial infarction randomized placebo controlled trial. Lancet 2005 366 1607-1621. 

Pedersen TR, Faergeman O, KasteleinJJ, etal, High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction the IDEAL study a randomized controlled trial. JAMA 2005 294 2437-2445,... 

IboleJF etal. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004 291 (5) 565-575. 

PC-stent CABO, coronary artery bypass graft surgery DISTINCT, Bio DivYsio stent in randomized control trial MACE, major adverse cardiac events MI, myocardial infarction NS, no significant difference TLR, target lesion revascularization. 

Lunde KSS, Aakhus S, Arnesen H, Forfang K. Intracoronary injections of autologous mononuclear bone marrow cells in acute anterior wall myocardial infarction the ASTAMI randomized controlled trial, In Scientific Sessions of the American Heart Association 2005, Internet communication, 2006,... 

MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction An overview of results from the randomized controlled trials. JAMA 1988 260 1910-6. 

Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980 243(7) 661-9. 

Intermittent claudication has also been reported to be worsened by beta-adrenoceptor antagonists, but has been difficult to document because of the difficulty of study design in patients with advanced atherosclerosis. As early as 1975 it was reported from one small placebo-controlled study that propranolol did not exacerbate symptoms in patients with intermittent claudication (70). This has subsequently been supported by the results of several large placebo-controlled trials of beta-blockers in mild hypertension and reports of trials of the secondary prevention of myocardial infarction, in which intermittent claudication was not mentioned as an adverse effect, even though it was not a specific contraindication to inclusion (71). In addition, a comprehensive study of the effects of beta-adrenoceptor antagonists in patients with intermittent claudication did not show beta-blockade to be an independent risk factor for the disease (72). In men with chronic stable intermittent claudication, atenolol (50 mg bd) had no effect on walking distance or foot temperature (73). These findings have been confirmed in a recent meta-analysis of 11 randomized, controlled trials to determine whether beta-blockers exacerbate intermittent claudication (SEDA-17, 234). 

Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAA4A 1992 268 240-8. 

S.R. Mehta, S. Yusuf, R. Diaz, J. Zhu, P. Pais, D. Xavier, E. Paolasso, R. Ahmed, C. Xie, K. Kazmi, J. Tai, A. Orlandini, J. Pogue, L. Liu CREATE-ECLA Trial Group Investigators, Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction the CREATE-ECLA randomized controlled trial, JAMA. 293(4), 437-446 (2005). 

Erne P, Schoenenberger AW, Burckhardt D, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction the SWISSI II randomized controlled trial. JAMA 2007 297(18) 1985-91. 

Aversano T, Aversano LT, Passamani E, Knattemd GL, Terrin ML, Williams DO, Forman SA Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT). Thrombolytic therapy vs. primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery a randomized controlled trial. JAMA 2002 287 1943-1951. 

Kastrati A, Mehilli J, Schlotterbeck K, Dotzer F, Dirschinger J, Schmitt C, Nekolla SG, Seyfarth M, Martinoff S, Markwardt C, Clermont G, Gerbig HW, Leiss J, Schwaiger M, Schomig A Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators. Early administration of reteplase plus abdximab vs. abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention a randomized controlled trial. JAMA 2004 291(8) 947-954. 

Kastrati A, MehUli J, Schlotterbeck K, et al. Early administration of reteplase plus abdximab vs. abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention a randomized controlled trial. JAMA. 2004 291 947-954. 

The APEX AMI investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention. A randomized controlled trial. JAMA 2007 297 43-51. 

The CREATE-ECLA Trial Group Investigators. Effect of glucose-insuhn-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction. The Create-Ecla randomized controlled trial. JAMA 2005 293 437-A46. 

Singh, R.B. et al.. Randomized controlled trial of cardioprotective diet in patients with recent acute myocardial infarction results of one year follow up, Brit. Med. J., 304, 1015, 1992. 

Toole, J.F., Malinow, M.R., Chambless, L.E., Spence, J.D., Pettigrew, L.C., Howard, V.J., Sides, E.G., Wang, C.H., and Stampfer, M., 2004. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA, the Journal of the American Medical Association. 291 565-575. 

Maynard, C., R. Swenson, J. A. Paris, J. S. Martin, A. P. Hallstrom, M. D. Cerqueira and W. D. Weaver, 1998, Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group. Am Heart] 135 797-804. 

In another meta-analysis of the cardiovascular effects of tiotropium, 19 randomized controlled trials in 18 III participants were pooled to look at the primary end-point of major adverse cardiovascular events, cardiovascular deaths, non-fatal myocardial infarctions, or strokes [94 ]. All the studies included tiotropium in one treatment arm. 

Dunkelgrun M, Boersma E, Schouten O, Koopman-van Gemert AW, van PF, Bax JJ, Thomson IR, Poldermans D. Biso-prolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery a randomized controlled trial (DECREASE-rV). Ann Surg 2009 249 (6) 921-6. 

Cardiovascular The effects of calcium supplementation on vascular disease have been studied in a large, randomized, controlled trial in healthy postmenopausal women over 5 years [18 ]. There was a substantial increase in rates of vascular events, particularly myocardial infarction, in women who were randomized to calcium. These effects were more marked in those who were highly compliant with treatment. Calcium supplementation also appears to accelerate vascular disease in patients with renal impairment, including those not yet requiring hemodialysis. 

---